SELLAS Life Sciences Group, Inc.SLSEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative cancer immunotherapies for patients with unmet medical needs. Its core pipeline targets both hematological malignancies and solid tumors, with lead product candidates addressing indications like acute myeloid leukemia, primarily serving markets across North America.
SLS Q1 FY2024 Key Financial Metrics
Revenue
$79.0K
Gross Profit
N/A
Operating Profit
$-9.6M
Net Profit
$-9.6M
Gross Margin
N/A
Operating Margin
-12208.9%
Net Margin
-12108.9%
YoY Growth
N/A
EPS
$-0.21
SELLAS Life Sciences Group, Inc. Q1 FY2024 Financial Summary
SELLAS Life Sciences Group, Inc. reported revenue of $79.0K for Q1 FY2024, with a net profit of $-9.6M (up 13.8% YoY) (-12108.9% margin).
Key Financial Metrics
| Total Revenue | $79.0K |
|---|---|
| Net Profit | $-9.6M |
| Gross Margin | N/A |
| Operating Margin | -12208.9% |
| Report Period | Q1 FY2024 |
Income Statement
| Q1 2024 | |
|---|---|
| Revenue | $79000 |
| YoY Growth | N/A |
Balance Sheet
| Q1 2024 | |
|---|---|
| Assets | $24.4M |
| Liabilities | $14.8M |
| Equity | $9.7M |
Cash Flow
| Q1 2024 | |
|---|---|
| Operating CF | $-10.8M |